CLDX — Celldex Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.27bn
- $1.55bn
- $1.55m
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials
Brief: Celldex Announces Positive Results From Phase 3 Embarq-Csu1 And Embarq-Csu2 Studies Of Barzolvolimab Which Met Primary And All Key Secondary Endpoints
Celldex Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Celldex Q2 net loss widens on higher R&D, G&A expenses
U.S. STOCKS ON THE MOVE-Wabtec, Chubb, CME Group
U.S. STOCKS ON THE MOVE-Wabtec, Johnson & Johnson, CME Group
U.S. STOCKS ON THE MOVE-GE Vernova, Arrowhead Pharma
Celldex falls after scrapping development of skin disease drug
Brief: Celldex Reports Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis
Celldex shares fall after it drops skin disease drug study
Celldex to stop skin disease study after trial setback
Celldex to stop skin disease study after trial setback
Brief: Celldex Announces Planned Transition Of Chief Financial Officer
Brief: Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study
Celldex Q1 net loss widens on lower services performed for Rockefeller University
U.S. STOCKS ON THE MOVE-Adobe, Biogen, Sable